Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
Sigyn Therapeutics, Inc. (RGNP)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/04/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/07/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modifications to Rights of Secu...|
Docs:
|
"SIGYN THERAPEUTICS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A CONVERTIBLE PREFERRED STOCK THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of Sigyn Therapeutics, Inc., a Delaware corporation , that the following resolution was duly adopted by the board of directors of the Corporation , in accordance with the provisions of Section 151 of the General Corporation Law of the State of Delaware, as amended on June 23, 2023, which resolution provides for the creation of a series of the Corporation’ s Preferred Stock, par value $0.0001 per share, which is designated as “Series A Preferred Stock,” with the rights, preferences, privileges and restrictions set forth therein. WHEREAS, the Amended and Restated Certificate of Incorporation of the Corporation , prov...",
"SHARE FOR WARRANT EXCHANGE AGREEMENT THIS WARRANT EXCHANGE AGREEMENT is made as of the 30 th day of June 2023, by and between Sigyn Therapeutics, Inc., a Delaware corporation located at 2468 Historic Decatur Road, Suite 140, San Diego, CA. 92106, and [Redacted] ." |
|
| 06/08/2023 |
8-K
| Other Events Interactive Data |
| 05/15/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/10/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 04/13/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 03/31/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/28/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 12/23/2022 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/07/2022 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 10/05/2022 |
8-K
| Quarterly results |
| 08/15/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 06/22/2022 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 05/13/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 03/21/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
| 03/09/2022 |
8-K
| Quarterly results |
| 03/01/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 02/04/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 11/12/2021 |
10-Q
| Quarterly Report for the period ended September 30, 2021 |
| 10/26/2021 |
8-K/A
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 10/25/2021 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ... |
| 08/16/2021 |
10-Q
| Quarterly Report for the period ended June 30, 2021 |
| 05/17/2021 |
10-Q
| Quarterly Report for the period ended March 31, 2021 |
| 05/14/2021 |
8-K
| Quarterly results |
| 04/06/2021 |
10-K
| Annual Report for the period ended December 31, 2020 |
| 03/31/2021 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405: |
| 01/27/2021 |
SC 13G/A
| Brio Capital Master Fund Ltd. reports a 10% stake in SIGYN THERAPEUTICS, INC. |
| 01/14/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 12/30/2020 |
8-K/A
| Financial Statements and Exhibits Interactive Data|
Docs:
|
"SIGYN THERAPEUTICS, INC. Index to Financial Statements CONTENTS Page Report of Independent Registered Public Accounting Firm 2 Balance Sheet 3 Statement of Operations 4 Statement of Changes in Stockholders’ Deficit 5 Statement of Cash Flows 6 Notes to Financial Statements 7 Report of Independent Registered Public Accounting Firm To the Board of Directors and Stockholders of Sigyn Therapeutics, Inc.",
"SIGYN THERAPEUTICS, INC. Index to Financial Statements CONTENTS Unaudited Condensed Financial Statements Page Unaudited Condensed Balance Sheets 2 Unaudited Condensed Statements of Operations 3 Unaudited Statements of Changes in Stockholders’ Deficit 4 Unaudited Condensed Statement of Cash Flows 5 Notes to Unaudited Condensed Financial Statements 6 SIGYN THERAPEUTICS, INC. UNAUDITED CONDENSED BALANCE SHEETS September 30, December 31, 2020 2019 ASSETS Current assets: Cash $ 365,145 $ - Total current assets 365,145 - Intangible assets 10,199 - Total assets $ 375,344 $ - LIABILITIES AND STOCKHOLDERS’ DEFICIT Current liabilities: Accounts payable $ 1,090 $ 910 Accrued payroll taxes 22,021 - Total current liabilities 23,111 910 Long-term liabilities: Convertible notes, net of unamortized debt d...",
"SIGYN THERAPEUTICS, INC. UNAUDITED PROFORMA CONDENSED COMBINED FINANCIAL STATEMENTS" |
|
| 11/09/2020 |
10-Q
| Quarterly Report for the period ended September 30, 2020 |
| 10/29/2020 |
SC 13G
| Osher Capital Partners LLC reports a 10% stake in SIGYN THERAPEUTICS INC. f/k/a REIGN RESOURCES CORPORATION |
| 10/23/2020 |
8-K
| Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity ... |
|
|
|